<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715752</url>
  </required_header>
  <id_info>
    <org_study_id>022015</org_study_id>
    <nct_id>NCT02715752</nct_id>
  </id_info>
  <brief_title>A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin</brief_title>
  <official_title>A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Center for the Biology of Chronic Disease</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Center for the Biology of Chronic Disease</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study measured the changes in health-related complaints by analyzing charts of
      individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The medical community calls the movement from severe to mild disease and from mild to normal
      health, 'relieving symptoms', and the interventions that cause such movement, drugs,
      medications, or therapies. The alternative community calls the movement from normal health to
      superior health, 'boosting health' (or boosting the immune system, or improving your sex
      drive, or boosting any another well functioning physiological system), and the interventions
      that cause such movement, natural remedies, dietary supplements, complementary treatments,
      etc. In general, these interventions aim to achieve superior performance of a normal human
      body. Of course, boosting the body's normal performance improves many of its capabilities,
      such as higher resistance to diseases, faster recovery from fatigue, better mental
      concentration, etc. Each movement presents different objectives. Relieving symptoms
      represents the ability of an intervention to reduce the frequency, duration, and severity of
      a disease. In contrast, boosting health represents the ability of an intervention to increase
      the frequency, duration, and quality of a person's health. In the current study, the
      investigators would like to measure the changes in health-related complaints by analyzing
      charts of individuals, who are infected with latent virus, and who have used
      Gene-Eden-VIR/Novirin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>frequency of symptoms</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>duration of symptoms</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to first recurrence</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">1000</enrollment>
  <condition>Herpes Simplex Infections</condition>
  <condition>Human Papillomavirus</condition>
  <condition>Epstein-Barr Virus Infections</condition>
  <condition>Varicella-zoster Virus Infection</condition>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>Herpes Simplex Virus Infection</arm_group_label>
    <description>Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Human Papillomavirus Infection</arm_group_label>
    <description>Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epstein-Barr Virus Infection</arm_group_label>
    <description>Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cytomegalovirus Infection</arm_group_label>
    <description>Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varicella Zoster Virus Infection</arm_group_label>
    <description>Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gene-Eden-VIR/Novirin</intervention_name>
    <arm_group_label>Herpes Simplex Virus Infection</arm_group_label>
    <arm_group_label>Human Papillomavirus Infection</arm_group_label>
    <arm_group_label>Epstein-Barr Virus Infection</arm_group_label>
    <arm_group_label>Cytomegalovirus Infection</arm_group_label>
    <arm_group_label>Varicella Zoster Virus Infection</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men and women ages greater than 18 years old
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Latent viral infection with either HSV, HPV, VZV, EBV, or CMV

          -  Taking Gene-Eden-VIR/Novirin

        Exclusion Criteria:

          -  Use of other antiviral treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Center for the Biology of Chronic Disease</name>
      <address>
        <city>Valley Cottage</city>
        <state>New York</state>
        <zip>10989</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>April 24, 2016</last_update_submitted>
  <last_update_submitted_qc>April 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

